Spots Global Cancer Trial Database for Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)
Official Title: To Assess the Correlation Between the Predictive Factor of Vascularity (CD74) in Malignant Pleural Mesothelioma and Treatment Results (Response Rate, and Overall Survival )
Study ID: NCT02603315
Conditions
Study Description
Brief Summary: The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .
Detailed Description: This is a randomized controlled retrospective study through Examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using Immunohistochemistry test methods.
Keywords
Eligibility
Minimum Age: 39 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ain Shams University Hospital, Cairo, , Egypt
Contact Details
Name: Amr S Saad, MD
Affiliation: Ain Shams University
Role: STUDY_DIRECTOR
Name: Mahmoud Ellithy, MD
Affiliation: Ain Shams University
Role: STUDY_CHAIR
Name: Doaa Atef, MD
Affiliation: Ain Shams University
Role: STUDY_DIRECTOR
Name: Hoda Abougabal, MD
Affiliation: Ain Shams University
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
